Negative feedback regulation of Homer 1a on norepinephrine-dependent cardiac hypertrophy

Carmelina Chiarello1, Elena Bortoloso1, Andrea Carpi1

  • 1Dipartimento di Scienze Biomediche dell'Università di Padova, Istituto Interuniversitario di Miologia, Istituto di Neuroscienze del CNR, Padova, Italy.

Insights

Homer 1a scaffolding protein expression increases during early cardiac hypertrophy. Overexpressed Homer 1a partially counteracts hypertrophy markers, suggesting a negative feedback role in cardiac cells.

Area of Science:

  • Cardiovascular Biology
  • Cellular Signaling
  • Molecular Cardiology

Background:

  • Homer proteins are scaffolding molecules crucial for assembling signaling complexes and modulating cellular functions.
  • Understanding the role of Homer proteins, particularly Homer 1, in cardiac physiology is essential for elucidating mechanisms of cardiac hypertrophy.

Purpose of the Study:

  • To investigate the expression, localization, and functional role of Homer 1 isoforms in cardiac muscle.
  • To determine the involvement of Homer 1 in norepinephrine-induced cardiac hypertrophy.

Main Methods:

  • Confocal immunofluorescence microscopy to assess sub-cellular distribution.
  • Western blot and quantitative PCR (qPCR) to analyze Homer 1 isoform expression.
  • Overexpression studies in HL-1 cells to evaluate functional effects on hypertrophy markers.

Main Results:

  • Homer 1a and Homer 1b/c are constitutively expressed in cardiac muscle and HL-1 cells.
  • Norepinephrine (NE) specifically upregulates Homer 1a, but not Homer 1b/c, in cardiomyocytes and HL-1 cells.
  • Overexpression of Homer 1a partially inhibited NE-induced ERK phosphorylation, ANF upregulation, and cell size increase, while Homer 1b/c had no effect.

Conclusions:

  • Homer 1a is upregulated during early stages of cardiac hypertrophy.
  • Homer 1a appears to exert a negative feedback regulation on molecular pathways driving cardiac hypertrophy.
  • Homer 1a, but not Homer 1b/c, plays a significant role in modulating cardiac hypertrophy responses.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Feedback Loops01:01

Feedback Loops

In most cases, excessive hormone production is prevented by negative feedback—a loop that starts with a stimulus inducing the release of a particular substance, like a hormone, to maintain a certain level before triggering a signal that results in a decrease in further release of the hormone.
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...